Pharmacological Treatment in Diabetes Mellitus Type 1 - Insulin and What Else?

Int J Endocrinol Metab. 2017 Nov 20;16(1):e13008. doi: 10.5812/ijem.13008. eCollection 2018 Jan.

Abstract

The basis of treatment in autoimmune diabetes is insulin therapy; however, many clinical cases have proven that this method does not solve all problems. Trials of causal treatment including blocking the autoimmune processes and insulin-producing cells transplants were carried out. Those methods require more research to be concerned as efficient and safe ways of treatment in type 1 diabetes. The use of non-insulin adjunct treatment is a new trend. It has been successfully used in laboratories as well as clinical trials. Metformin is the most widely used drug, together with sodium-glucose co-transporters 2 (SGLT2) inhibitors, amylin analogues, glucagon-like peptide 1 (GLP-1) receptor agonists, and dipeptidyl peptidase-4 (DPP-4) inhibitors. The results of administration of these medicaments give good outcomes in patients with diabetes mellitus type 1. Most likely, in the near future, they will progressively be used in both adult and adolescent patients with type 1 diabetes. Further multicenter, randomized studies are required to evaluate the efficacy of treatment and long term safety of these drugs.

Keywords: Amylin Analogue; Dipeptidyl Peptidase-4 (DPP-4) Inhibitors; Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists; Insulin Therapy; Metformin, SGLT2: Sodium-Glucose Co-Transporters; Non-Insulin Adjunct Therapy; Type 1 Diabetes.

Publication types

  • Review